Foresite Capital Management VI LLC
Foresite Capital Management VI LLC reported 23 US-listed holdings worth $642.6 million in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: CG Oncology Inc. (26.2%), Alumis Inc. (18.6%) and Seaport Therapeutics Inc. (6.0%). Against the quarter before, it opened 8 positions, added to 6, trimmed 0 and sold out of 2.
The 14 largest of its 23 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +140.1% over the 6 quarters to 30 June 2026, against +27.4% for the S&P 500.
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 8
- Seaport Therapeutics Inc. SPTX$38.7 million
- Parabilis Medicines Inc. Com PBLS$27.3 million
- Beam Therapeutics Inc. BEAM$11.3 million
- Arrivent Biopharma Inc. AVBP$10.5 million
- Aura Biosciences Inc. AURA$9.5 million
- Research Alliance Corp Iii Ord Shs Cl A RACC$3.2 million
- Kailera Therapeutics Inc. KLRA$826,125
- Disc Medicine Inc. IRON$70,946
Added to 6
- Celldex Therapeutics Inc. CLDX+563,800 shares · +178%
- GH Research PLC GHRS+625,001 shares · +198%
- Jade Biosciences Inc. JBIO+566,667 shares · +177%
- CG Oncology Inc. CGON+148,100 shares · +7%
- Agios Pharmaceuticals Inc. AGIO+260,000 shares · +50%
- Denali Therapeutics Inc. DNLI+186,800 shares · +15%
Sold out of 2
- Centessa Pharmaceuticals PLC CNTA$54.2 million last quarter
- Onkure Therapeutics Inc OKUR$6.0 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| CG Oncology Inc. CGON | 2.4M | $168.4 million | 26.20% | +148.1K |
| Alumis Inc. ALMS | 4.2M | $119.5 million | 18.60% | no change |
| Seaport Therapeutics Inc. SPTX | 1.8M | $38.7 million | 6.02% | new |
| Denali Therapeutics Inc. DNLI | 1.4M | $35.9 million | 5.59% | +186.8K |
| Celldex Therapeutics Inc. CLDX | 879.7K | $32.7 million | 5.09% | +563.8K |
| Agios Pharmaceuticals Inc. AGIO | 785.0K | $29.1 million | 4.53% | +260.0K |
| Corvus Pharmaceuticals Inc. CRVS | 1.8M | $27.4 million | 4.26% | no change |
| Parabilis Medicines Inc. Com PBLS | 999.0K | $27.3 million | 4.26% | new |
| GH Research PLC GHRS | 940.5K | $25.3 million | 3.93% | +625.0K |
| Jade Biosciences Inc. JBIO | 886.7K | $19.7 million | 3.07% | +566.7K |
| Hinge Health Inc. HNGE | 220.4K | $18.3 million | 2.85% | no change |
| Kymera Therapeutics Inc. KYMR | 146.3K | $16.8 million | 2.61% | no change |
| Atai Beckley NV ATAI | 2.8M | $14.5 million | 2.26% | no change |
| Verastem Inc. VSTM | 3.1M | $12.0 million | 1.87% | no change |
| Beam Therapeutics Inc. BEAM | 330.0K | $11.3 million | 1.76% | new |
| Minerva Neurosciences Inc. NERV | 2.0M | $11.0 million | 1.71% | -1.0K |
| Arrivent Biopharma Inc. AVBP | 301.3K | $10.5 million | 1.63% | new |
| Aura Biosciences Inc. AURA | 1.3M | $9.5 million | 1.47% | new |
| Crinetics Pharmaceuticals in CRNX | 212.0K | $7.9 million | 1.23% | no change |
| Research Alliance Corp Iii Ord Shs Cl A RACC | 300.0K | $3.2 million | 0.50% | new |
| Zura Bio Ltd ZURA | 450.0K | $2.7 million | 0.41% | no change |
| Kailera Therapeutics Inc. KLRA | 37.5K | $826,125 | 0.13% | new |
| Disc Medicine Inc. IRON | 970 | $70,946 | 0.01% | new |